AstraZeneca Investor Day Presentation Deck
Adverse events of special interest
Adjudicated as drug-related ILD/pneumonitis¹, n (%)
n (%)
Grade 1
Grade 2
Grade 4
T-DXd (n = 257)
7 (2.7)
0
18 (7.0)
1 (0.4)
0
T-DM1 (n = 261)
4 (1.5)
There were no grade 4 or 5 adjudicated drug-related ILD/pneumonitis events observed with T-DXd
LVEF, n (%)
n (%)
Grade 1
Grade 2
Grade 3
2 (0.8)
0
Grade 3
Grade 4
ILD, interstitial lung disease; LVEF, left-ventricular ejection fraction.
1. Patients with prior history of ILD/pneumonitis requiring steroids were excluded 2. Left ventricular dysfunction 3. Decreased ejection fraction.
16
Grade 5
0
0
Grade 5
T-DXd (n = 257)
1 (0.4)²
0
0
0
6 (2.3)³
1 (0.4) ³
T-DM1 (n = 261)
0
0
0
0
In the T-DXd arm, all LVEF adverse events reported were asymptomatic and no cases of cardiac failure occurred
Any Grade
27 (10.5)
5 (1.9)
Any Grade
7 (2.7)
1 (0.4)
3View entire presentation